You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《盈警響號》常茂生物(00954.HK)料去年未扣除減值等淨利潤降至最多3,400萬人幣
阿思達克 03-05 16:42
常茂生物(00954.HK)公布,集團很有可能錄得截至去年12月31日止年度,在未考慮扣除其附屬公司,連雲港常茂的物業、機器及設備的減值損失及沖銷遞延稅項資產前之綜合淨利潤約2,700萬元人民幣(下同)至3,400萬元,將較2019年度的綜合淨利潤約5,829.9萬元大幅下降。

集團指,主要由於去年初COVID-19疫情的爆發,導致客戶需求減弱以及集團產品平均售價下降導致毛利率下降。為配合政府政策變更,公司必須關閉及搬遷位於常州受影響工廠區的某些生產線。集團於去年6月停止生產順酐。在此之前,集團在常州一期廠房生產了部分供其他產品作原材料的的順酐。自停止生產順酐後,集團需全部從第三方購買順酐。於去年第四季起,順酐價格大幅上升;此外,集團不能夠再循環利用順酐生產過程中產生的蒸汽而得益。這些因素使得集團的生產成本增加,導致毛利率下降。

此外,去年集團預期將對連雲港常茂的物業、機器及設備做出減值準備及部分遞延稅項資產予以沖銷。為了配合連雲港政府政策和集團的長遠發展計劃,集團將把連雲港常茂的順酐生產線搬遷到即將興建的大連工廠。由於營運調整,將導致一些物業、機器及設備不能再使用以及部分有關結轉稅務虧損的遞延稅項資產將不可能實現。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account